Amgen (AMGN)
298.08
+5.57 (1.90%)
NASDAQ · Last Trade: Jul 16th, 1:35 PM EDT
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Via StockStory · July 15, 2025
Via The Motley Fool · July 14, 2025
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via Benzinga · July 11, 2025
Via Benzinga · July 10, 2025
Via Benzinga · July 10, 2025
Via The Motley Fool · July 3, 2025
Wall Street optimistic for July 4 weekend, sees opportunities in Freeport-McMoRan, Honeywell, Caterpillar, and Amgen. Analysts raise targets.
Via Benzinga · July 3, 2025
Via The Motley Fool · July 1, 2025
The Dow Jones Industrial Average stocks average a 2% dividend yield through the first six months of 2025. Here are the top yields.
Via Benzinga · July 1, 2025
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide.
Via Investor's Business Daily · June 30, 2025
Amgen's Phase 3 trial of bemarituzumab plus chemo met its survival goal in FGFR2b+ gastric cancer, with full data expected later.
Via Benzinga · June 30, 2025
Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival as compared to placebo plus chemotherapy in the trial.
Via Stocktwits · June 30, 2025
Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.
Via Benzinga · June 24, 2025
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of MariTide.
Via Benzinga · June 23, 2025
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via Chartmill · June 23, 2025
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies.
Via Investor's Business Daily · June 23, 2025
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
Via Benzinga · June 20, 2025
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence.
With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Via StockStory · June 20, 2025
The Democratic lawmakers alleged that pharmaceutical companies avoided paying U.S. tax bills by shifting their profits to offshore subsidiaries in jurisdictions with significantly lower tax rates, such as Ireland and Bermuda, according to CNBC.
Via Stocktwits · June 17, 2025